A recent study by Labussiere and colleagues also demonstrated that combined analysis of TERTp, EGFR and IDH1/2 defined distinct prognostic classes in glioblastomas, with the absence of both EGFR amplification and TERTp mutation associating with longer survival in patients with glioblastomas [22]. Here, EGFR is linked to glioblastoma.